NANJING, China, July 13, 2026
Leads Biolabs has strengthened its position in global cancer immunotherapy after announcing that six clinical research studies from its oncology pipeline have been accepted for presentation at the European Society for Medical Oncology (ESMO) 2026 Annual Congress, one of the world’s premier oncology scientific meetings. Among the accepted studies, two have been selected as Proffered Papers, the congress’s highest-profile oral presentation category reserved for research with exceptional scientific significance and clinical impact, while four additional studies will be presented as scientific posters. Furthermore, the company has secured Late-Breaking Abstract (LBA) status, reflecting the potential of emerging clinical findings that may influence future cancer treatment practices. The accepted studies span multiple difficult-to-treat cancers, including extrapulmonary neuroendocrine carcinoma (EP-NEC), biliary tract cancer (BTC), and relapsed or refractory multiple myeloma (RRMM), highlighting the expanding clinical potential of Leads Biolabs’ innovative oncology portfolio. The ESMO 2026 Congress, scheduled to take place in Madrid, Spain, from October 23–27, 2026, will provide an international platform to showcase the company’s latest advances in precision immunotherapy and reinforce its growing reputation among the global oncology community.
Multiple ESMO Selections Highlight Clinical Strength
The acceptance of six independent studies demonstrates the increasing scientific recognition of Leads Biolabs’ clinical development strategy and validates the progress of its proprietary immuno-oncology platforms. Proffered Paper presentations represent one of the highest honors at ESMO and are reserved for studies expected to make a significant contribution to clinical oncology practice. In addition, the company’s Late-Breaking Abstract designation indicates that newly generated clinical data possess the potential to influence future treatment standards and will be submitted for final evaluation in September. Together, these achievements reflect the growing competitiveness of the company’s research programs and underscore confidence in its ability to generate clinically meaningful outcomes across multiple solid tumors and hematologic malignancies. The full clinical datasets will become available through ESMO’s official abstract publication and scientific presentations during the congress, offering oncologists worldwide new insights into emerging cancer therapies.
Core Pipeline Demonstrates Broad Oncology Potential
A major focus of the presentations will be Opamtistomig, Leads Biolabs’ investigational PD-L1/4-1BB bispecific antibody, which has continued to generate encouraging clinical evidence across several tumor types. According to company leadership, Opamtistomig has demonstrated deep and durable treatment responses, encouraging survival outcomes, and a well-tolerated safety profile, reinforcing its potential to serve as a next-generation IO 2.0 pan-tumor backbone therapy. The company also highlighted the continued progress of LBL-034, which further validates the global competitiveness of its proprietary LeadsBody T-cell engager (TCE) platform, designed to improve targeted immune responses against cancer cells. In addition to its strong ESMO presence, Leads Biolabs previously announced that Opamtistomig had also been selected for an oral presentation at the 2026 World Conference on Lung Cancer (WCLC), where new clinical findings in first-line non-small cell lung cancer (NSCLC) will be presented. These multiple international conference selections reinforce the scientific momentum behind the company’s expanding oncology pipeline.
Advertisement
Global Recognition Supports Future Clinical Development
The strong representation at ESMO 2026 reflects Leads Biolabs’ growing influence in the global oncology research landscape and supports its long-term strategy of advancing innovative immunotherapies toward global registrational clinical trials and commercialization. By securing multiple high-profile presentations at leading international oncology congresses, the company continues to strengthen confidence among clinicians, researchers, regulators, and potential partners regarding the therapeutic potential of its core assets. As cancer immunotherapy continues to evolve beyond traditional checkpoint inhibitors toward next-generation bispecific antibodies and T-cell engager technologies, Leads Biolabs is positioning itself among the emerging innovators driving precision oncology. The forthcoming ESMO presentations are expected to provide important clinical evidence supporting future regulatory development while reinforcing the company’s commitment to delivering transformative therapies for patients with cancers that continue to have significant unmet medical needs.
Source: Leads Biolabs press release
